| Original language | English |
|---|---|
| Pages (from-to) | 1342-1354 |
| Number of pages | 13 |
| Journal | Journal of Proteomics |
| Volume | 73 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 7 May 2010 |
| Externally published | Yes |
Funding
We thank Olga Brueck for her assistance in preparing the manuscript and to Thomas Froehlich for his assistance with the LC-MS/MS analysis and MS data analysis Furthermore we thank Susanne Schwarzmaier, Micaela Gallozzi and John Guenn for carefully reading the manuscript This work was funded by the EU project GIANT.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Austrian Fields of Science 2012
- 301207 Pharmaceutical chemistry
Keywords
- Antiangiogenesis
- Metronomic
- Low dose chemotherapy
- Prostate cancer
- Proteomics
- Annexin A3
- In vivo chemoresistance
- HUMAN CATHEPSIN-B
- TUMOR ANGIOGENESIS
- HEPATOCELLULAR-CARCINOMA
- MULTIDRUG-RESISTANCE
- VASCULOGENIC MIMICRY
- SIDE POPULATION
- PHASE-II
- CELLS
- THIOREDOXIN
- EXPRESSION
Fingerprint
Dive into the research topics of 'In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver